Holly Ryan

Holly Ryan

Auto-generated profile, based on publicly available information

Holly Ryan

J. Crayton Pruitt Family Department of Biomedical Engineering

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2021 in Regenerative Engineering and Translational Medicine
Verified
Journal Article
Closed access
PDF file
HRHolly Ryan
Holly Ryan
DBDaniel Bister
Daniel Bister
SHSophia A Holliday
Sophia A Holliday
JBJessica Boehlein
Jessica Boehlein
ALAljae Lewis
Aljae Lewis
EMErika Moore
Erika Moore

1 April 2021 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
JSJustin Silberman
Justin Silberman
AJAakanksha Jha
Aakanksha Jha
HRHolly Ryan
Holly Ryan
TATalia Abbate
Talia Abbate
EMErika Moore
Erika Moore

16 February 2024 in Journal of Proteome Research
Verified
Journal Article
Open access
CPCarlos H. Pavan
Carlos H. Pavan
ZAZaraah Abdoollah
Zaraah Abdoollah
DRDaniel E. Marrero Roche
Daniel E. Marrero Roche
HRHolly R. Ryan
Holly R. Ryan
EMErika Moore
Erika Moore
KCKevin Chandler
Kevin Chandler
Fc γ-receptors (FcγRs) on leukocytes bind immunoglobulin G (IgG) immune complexes to mediate effector functions. Dysregulation of FcγR-mediated processes contributes to multiple inflammatory diseases, including rheumatoid arthritis, lupus, and immune thrombocytopenia. Critically, immunoregulatory N-glycan modifications on both FcγRs and IgGs alter FcγR-IgG binding affinity. Rapid methods for the characterization of N-glycans across multiple Fcγ receptors are needed to propel investigations into disease-specific contributions of FcγR N-glycans. Here, we utilize nanoliquid chromatography tandem mass spectrometry (nLC-MS/MS) to characterize FcγR glycosylation and report quantitative and site-specific N-glycan characterization of recombinant human FcγRI, FcγRIIIA V158, and FcγRIIIA F158 from CHO cells and murine FcγRI, FcγRIII, and FcγRIV from NS0 cells. Data are available via ProteomeXchange with identifier PXD043966. Broad glycoform distribution (≥30) was observed at mouse FcγRIV site N159 and human FcγRIIIA site N162, an evolutionarily conserved site. Further, mouse FcγRIII N-glycopeptides spanning all four predicted N-glycosylation sequons were detected. Glycoform relative abundances for hFcγRIIIA V/F158 polymorphic variants are reported, demonstrating the clinical potential of this workflow to measure differences in glycosylation between common human FcγRIIIA allelic variants with disease-associated outcomes. The multi-Fcγ receptor glycoproteomic workflow reported here will empower studies focused on the role of FcγR N-glycosylation in autoimmune diseases.

31 August 2020 in Cellular and Molecular Bioengineering
Verified
Journal Article
Closed access
PDF file
HRHolly Ryan
Holly Ryan
CSChelsey S. Simmons
Chelsey S. Simmons

10 November 2023 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
HRHolly Ryan
Holly Ryan
AVAlison Veintimilla
Alison Veintimilla
CGChristine Groso
Christine Groso
EMErika Moore
Erika Moore